NeuFit Revolutionizes Neurological Rehabilitation with Innovative NEUBIE Device

06 February 2025 | Thursday | News

Recent study published in the Journal of Diabetes Research highlights NeuFit's groundbreaking collaboration with Hands-On Diagnostics (HODS), demonstrating significant improvements in treating diabetic peripheral neuropathy through advanced diagnostics and direct current (DC) electrical stimulation.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

 NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and therapeutic technologies. At the center of NeuFit's success is the NEUBIE (Neuro-Bio-Electric Stimulator), a cutting-edge device that utilizes direct current (DC) electrical stimulation to promote accelerated recovery, enhance performance, and improve overall well-being. A recently published study in the Journal of Diabetes Research highlights NeuFit's unique approach in collaboration with Hands-On Diagnostics (HODS) to address neuropathy. The study shows striking results through a comparison of the NEUBIE device to traditional transcutaneous electrical nerve stimulation (TENS) devices for treating diabetic peripheral neuropathy. Treatment with the NEUBIE significantly improved pain reduction, motor function, sensory deficits, and nerve conduction, while TENS showed no significant improvements.

Unlike conventional methods that primarily focus on structural rehabilitation, the NEUBIE targets the nervous system, the body's control center for responses to injury or dysfunction. The use of DC over traditional alternating current (AC) in the NEUBIE device sets NeuFit apart from other electrical stimulation therapies. This promotes healing, reduces pain, and improves sensorimotor function more rapidly than AC, which can hinder effective therapy and reinforce inefficient movement patterns.

Neuropathy, characterized by nerve damage that results in pain, weakness, and numbness, presents significant treatment challenges. NeuFit and HODS are making groundbreaking strides in this area by combining advanced diagnostics with innovative therapy. HODS specializes in electromyography (EMG) and nerve conduction studies, providing detailed insights into nerve function. By integrating these diagnostic tools with NeuFit's therapeutic approach, patients receive comprehensive evaluations and tailored treatment plans that can be adjusted in real-time for optimal results.

"The findings from this study show that we can make tangible improvements to nerve function and related subjective measures in patients suffering from neuropathy," continues Dr. von Leden. "NeuFit's innovative approach, combined with HODS' diagnostic expertise, is redefining neurological rehabilitation. By focusing on the nervous system and leveraging advanced technology, NeuFit offers a promising future for patients with challenging conditions like neuropathy."

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close